启明医疗
您对本网站的 Cookie 选择
我们使用 Cookie 来确保此网站的正常运行并改善您的网站使用体验。单击“接受 Cookie”以同意当前的 Cookie 设置，或单击“隐私政策”查看有关正在使用的 Cookie 的详细信息。
杭州启明医疗器械股份有限公司只此一个网站，请仔细辨别，增强网络安全意识。
{/pboot:if} {pboot:if('{pboot:sitelanguage}'=='cn')}{pboot:slide num=2 gid=1}
- {/pboot:slide}
{pboot:slide num=2 gid=1}
- [slide:i]
{/pboot:slide}{pboot:slide num=2 gid=2}
- {/pboot:slide}
{pboot:slide num=2 gid=1}
- [slide:i]
{/pboot:slide}
公司概览
---------
启明医疗成立于2009年，位于杭州国家高新技术产业开发区（滨江），致力于结构性心脏病经导管治疗产品的研发和产业化。公司已于2019年12月10日在香港联交所主板上市，股票代码为02500。
公司全系列「中国智造」瓣膜产品已经走进全球60多个国家和地区，足迹涉及亚洲、欧洲、南美和北美地区。目前，启明医疗已建立了一个全面的结构性心脏病整体解决方案，覆盖主动脉瓣、肺动脉瓣、二尖瓣、三尖瓣等心脏瓣膜疾病，高血压肾动脉去交感神经消融术以及手术配套产品等完整管线。
{pboot:sort scode='1'} {/pboot:sort}{pboot:nav parent=5} [nav:name]-解决方案 {/pboot:nav}
+
+员工数量
+专利申请数量
+真实世界植入病例
年最长临床随访时长
+全国覆盖中心数量
.43%即刻安全手术比例
数据截至{pboot:companydataasof}
{/pboot:if} {pboot:if('{pboot:sitelanguage}'=='en')}全球化布局
中国
俄罗斯
泰国
马来西亚
新加坡
印度
巴基斯坦
欧洲
奥地利，比利时，荷兰，意大利，西班牙，葡萄牙，丹麦，波兰，瑞士，英国，希腊，芬兰，塞浦路斯，匈牙利，瑞典，挪威，德国，法国，爱尔兰，土耳其，摩纳哥， 保加利亚，克罗地亚，捷克共和国，立陶宛，罗马尼亚，斯洛伐克，斯洛文尼亚，爱沙尼亚，拉脱维亚，卢森堡，马耳他，冰岛，列支敦士登加拿大
墨西哥
巴西
智利
阿根廷
中国香港
中国澳门
乌拉圭
哥伦比亚
中东
迪拜，沙特阿拉伯，约旦，卡塔尔，埃及，摩洛哥，巴林，科威特，以色列吉尔吉斯斯坦
哈萨克斯坦
委内瑞拉
澳大利亚
VENUSMEDTECH
Your Cookie Choices for this Website
We use cookies to ensure the proper functioning of this website and to improve your website experience. Click "Accept Cookies" to agree to the current cookie settings, or click"Privacy Policy" to view detailed information about the cookies in use.
This is the only official website of Venus Medtech (Hangzhou) Inc., please read it carefully and enhance your network security awareness.
{pboot:slide num=2 gid=4}
- {/pboot:slide}
{pboot:slide num=2 gid=4}
- [slide:i]
{/pboot:slide}{pboot:slide num=2 gid=3}
- {/pboot:slide}
{pboot:slide num=2 gid=3}
- [slide:i]
{/pboot:slide}
Company Overview
---------
Founded in 2009, Venus Medtech is located in Hangzhou National High-Tech Industrial Development Zone (Binjiang) and is committed to the development and industrialization of transcatheter therapy products for structural heart disease. On December 10th, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (SEHK) with stock code 02500.
The company's all series of “China Intelligently Manufactured " valves has been introduced to more than 60 countries and regions worldwide, including Asia, Europe, South America. Venus Medtech has established comprehensive solutions for structural heart disease, with a complete product pipeline covering all four heart valves, namely TAVR, TPVR, TMVR and TTVR, as well as hypertensive renal denervation (RDN) therapy and relevant accessory products.
{pboot:sort scode='18'} {/pboot:sort}{pboot:nav parent=23} [nav:name]-Solutions {/pboot:nav}
+
+Employees
Patent applications
Real-world implantation cases
The longest duration of clinical follow-up
Centers nationwide
Proportion of immediate safe surgery
Data as of end of {pboot:companydataasof}
{/pboot:if} {pboot:if('{pboot:sitelanguage}'=='cn')} {include file=foot-i.html}{/pboot:if} {pboot:if('{pboot:sitelanguage}'=='en')} {include file=en-foot-i.html}{/pboot:if}Global landscape
China
Russia
Thailand
Malaysia
Singapore
India
Pakistan
Europe
Austria,Belgium,Netherlands,Italy,Spain,Portugal,Denmark,Poland,Switzerland,UK,Greece,Finland,Cyprus,Hungary,Sweden,Norway,Germany,France,Ireland,Turkey,Monaco,Bulgaria,Croatia,Czech Republic,Lithuania,Romania,Slovakia,Slovenia,Estonia,Latvia,Luxemburg,Malta,Iceland,LiechtensteinCanada
Mexico
Brazil
Chile
Argentina
HKSAR
Macao SAR
Uruguay
Colombia
Middle East
Dubai,Saudi Arabia,Jordan,Qatar,Egypt,Morocco,
Bahrain,Kuwait,IsraelKyrgyzstan
Kazakhstan
Venezuela
Australia